Probiotics in Liver Health Protection

Non-invasively detecting non-alcoholic fatty liver disease (NAFLD) in a subject by measuring the amount of Lactococcus lactis and/or Dorea sp. 5-2 microbial DNA in a biological sample from the subject and comparing it to a healthy control. Elevated levels of these microbes are biomarkers indicative of NAFLD.

Source

Compositions and methods for treating liver disorders like non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibrosis, and cirrhosis by administering a consortium of isolated and purified microbial species to improve gut function and reduce liver injury markers. The microbial compositions are formulated in ingestible forms like pills, capsules, or powders. The compositions contain specific bacterial strains like Akkermansia muciniphila, Bifidobacterium, Clostridium, Eubacterium, and Faecalibacterium that produce beneficial short chain fatty acids. Administering these microbes reduces elevated liver enzymes, indicating improved liver health.

Source

A lactic acid bacterium called Weissella hellenica WiKim0103, isolated from Kimchi, with potential to prevent or improve fatty liver disease and inflammation. It showed an inhibitory effect on intracellular fat accumulation and reduction of fatty liver-related gene expression.

Source

Probiotic bacteria and composition for preventing and treating non-alcoholic fatty liver disease. The composition contains a specific strain of lactobacillus rhamnosus called LR-Y12. The composition is made by fermenting a traditional Chinese medicine compound extract containing pectin, dark plum fruit, medlar, cassia seed, ginseng, and dried ginger with the LR-Y12 probiotic. This composition has synergistic effects on body weight reduction, fatty liver relief, and liver protection.

Source

Strain of Lactobacillus formosan called Lt259 that has preventive and therapeutic effects on non-alcoholic fatty liver disease (NAFLD). The strain is isolated from human feces and shown to reduce liver pathology, improve liver function, lower cholesterol, triglycerides, and LDL, decrease inflammation markers, lower endotoxin levels, and regulate intestinal flora in rats with NAFLD. Lt259 has properties like hydrophobicity, self-aggregation, antioxidant ability, and resistance to antibiotics. The strain can be used in products to prevent, improve, or treat NAFLD, hyperlipidemia, inflammation, and intestinal flora imbalances.

Source

Using Lactobacillus plantarum J26 strain and a composition containing it to alleviate acute-on-chronic alcoholic liver injury. The strain, isolated from kimchi, has good alcohol tolerance and intestinal colonization properties. It reduces alcohol-induced liver cell apoptosis, oxidative stress, inflammation, and intestinal damage. Compounding J26 with plants like kudzu root, vine tea, fructooligosaccharides, and hyaluronic acid further improves the effect.

Source

Pediococcus pentosaceus strain A21243 that reduces fat accumulation and treats non-alcoholic fatty liver disease. The strain can lower fat levels, inhibit cholesterol synthesis, promote bile acid synthesis, improve glucose tolerance, and reduce insulin resistance in models of non-alcoholic fatty liver disease. It also reduces liver damage, inflammation, and cholestasis. The strain is useful in medicines for preventing/treating non-alcoholic fatty liver disease, fat reduction, and metabolic dysfunction associated with non-alcoholic fatty liver.

Source

Using Lactobacillus plantarum strain A21094 to prevent and treat non-alcoholic fatty liver disease. The strain improves liver tissue morphology, lowers cholesterol and triglycerides, reduces inflammation, and enhances glucose tolerance. It achieves these effects by inhibiting cholesterol synthesis, promoting bile acid synthesis, regulating fatty acid synthesis, and suppressing inflammatory signaling.

Source

Lactobacillus plantarum ZJUIDS14 for improving non-alcoholic fatty liver disease. The lactobacillus plantarum is inhibiting the reproduction of other harmful germs in intestines and stomach, keep and ensure the best advantage composition of beneficial germs and the stability of the composition, block the colonization and invasion of pathogenic germs, inhibit the growth and development of pathogenic germs and harmful microorganism strains and the adhesion of endotoxin.

Source

Probiotic composition containing Lactobacillus acidophilus LA-G80 and Bifidobacterium bifidum BB-G90 strains for liver protection. The composition can reduce liver damage markers, improve liver function, and normalize inflammatory responses in liver injury models. It also optimizes gut microbiota and boosts immunity. The strains are lactic acid bacteria isolated from elderly and healthy individuals, respectively.

Source

A probiotic composition containing specific strains of Lactobacillus acidophilus (LA85) and Bifidobacterium longum (BL21) in a 1:1 ratio for improving chronic alcohol-induced liver disease. Administering this probiotic composition to mice with chronic alcohol-induced liver disease reduced liver lipid accumulation, liver damage, and alcohol-induced hepatocyte apoptosis compared to the mice only consuming alcohol.

Source

A probiotic composition containing specific strains of lactic acid bacteria to improve alcoholic fatty liver disease. The composition includes Lactobacillus rhamnosus strain LRa05 and Lactobacillus plantarum strain Lp05. Administering these probiotics can prevent, alleviate, or treat alcoholic fatty liver disease, chronic liver injury, liver fibrosis, cirrhosis, or liver cancer. The probiotics improve alcoholic fatty liver by reducing inflammation, oxidative stress, serum triglycerides, and intestinal permeability.

Source

Lactobacillus paracasei strain isolated from yak yogurt that alleviates alcohol-induced liver and gastric injury. The strain improves antioxidant capability in liver and gastric tissue, prevents inflammation, and recovers tissue structure. It also prolongs drunkenness time and shortens sober-up time. The strain can be used in preparations for preventing drunkenness, alleviating hangovers, reducing liver and gastric injury, and improving antioxidant and anti-inflammatory responses.

Source

Lactobacillus fermentum strain A21252 that relieves hangover, protects the liver, resists oxidative damage, and reduces digestive tract damage. The strain has characteristics like Lactobacillus fermentum and is isolated from the feces of a centenarian. It survives in simulated gastric and intestinal fluids. The strain degrades ethanol in vitro and in vivo, increases alcohol and acetaldehyde dehydrogenase activities, reduces liver tissue damage from drinking, protects liver function, reduces oxidative stress, and reduces digestive tract damage from alcohol.

Source

A strain of Lactobacillus reuteri, CCFM1132, that is capable of relieving hyperuricemia as well as a pharmaceutical composition containing the strain. The strain can reduce serum uric acid levels, inhibit liver xanthine oxidase activity, reduce creatinine levels, reduce serum triglycerides, reduce alkaline phosphatase activity, and increase expression of the ileum uric acid transporter ABCG2.

Source

A composition for improving hepatic function using a green tea-derived Lactiplantibacillus plantarum strain. It can be used to prevent and treat fatty liver disease. The strain, culture, lysate or extract of the Lactiplantibacillus plantarum is administered to improve liver health.

Source

Using a specific strain of Lactobacillus plantarum bacteria called P9 to prevent and treat non-alcoholic fatty liver disease (NAFLD). The strain P9 restores intestinal barrier integrity, reduces inflammation, and improves liver function in a mouse model of NAFLD. P9 supplementation offsets defects in intestinal barrier function, maintains intestinal homeostasis, and regulates immune responses to prevent translocation of endotoxins and inflammatory molecules into the liver. It also modulates gut microbiota composition and alters gene expression pathways like p53 and PPAR-a to maintain lipid metabolism homeostasis.

Source

Protecting alcoholic liver injury. The composition comprises lactobacillus paracasei JN-8 freeze-dried bacterial powder, polyphenol compounds and vitamins, wherein the lactobacillus paracasei JN-8 is preserved in China general microbiological culture Collection center (China general microbiological culture Collection center) at the 21 st month of 2021, and the preservation address is no.

Source

Using Megalococcus escherichia, a bacterial strain found in the human gut, for preventing and treating fatty liver, protecting liver function, and improving liver health. The strain, named Megalococcus escherichia, has liver-protective effects when administered to animals with fatty liver induced by a high-fat diet. The bacterial strain improves steatosis, reduces triglyceride deposition, improves gene expression related to cholesterol transport, and repairs liver damage. It shows potential as a probiotic and supplement for preventing and treating fatty liver and protecting liver health.

Source

Probiotic composition for relieving non-alcoholic fatty liver disease. The composition contains specific strains of lactic acid bacteria, including Lactobacillus plantarum HA-119, Lactobacillus casei Rosell-0215, and Lactobacillus rhamnosus Rosell-0052, in a specific ratio. The composition aims to alleviate non-alcoholic fatty liver disease by modulating intestinal flora to reduce liver inflammation and improve liver function. The composition can be used in functional foods, beverages, and supplements to manage non-alcoholic fatty liver disease.

Source